NCT02541344

Benefit of IQP-VV-102 in Reducing Postprandial Glucose Level in Overweight Caucasian Subjects

Double-blind, Randomised, Placebo-controlled, Three-way Crossover Clinical Investigation to Evaluate the Benefit of IQP-VV-102 in Reducing Postprandial Glucose Level in Overweight Caucasian Subjects

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 27 (estimated)
• Sponsor: InQpharm Group · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

In this trial, the investigational product , the active ingredients which has been proven to reduce postprandial glucose in healthy and diabetic patients, will be tested. The primary aim of this clinical study is to evaluate the possibility of the investigational product to reduce the rise of postprandial glucose AUC level in overweight Caucasian subjects with normal to prediabetic biomarkers (IFG/HbA1C), without prompting a disproportionate rise in insulin levels.

Conditions

• Prediabetes
• Hyperglycemia

Interventions

Type	Name	Description
DEVICE	Dose 1 of IQP-VV-102	Dose 1 (D1) group will take 2 tablets with active ingredients and 2 placebo tablets.
DEVICE	Dose 2 of IQP-VV-102	Dose 2 (D2) group will take 4 tablets with active ingredients.
DEVICE	Placebo	Placebo group will take 4 placebo tablets. The placebo is designed to be identical to IQP-VV-102.

Timeline

• Start date: 2014-06-01
• Primary completion: 2015-10-01
• First posted: 2015-09-04
• Last updated: 2015-11-10

Locations

1 site across 1 country: Germany